Among high responders, is oocyte development potential different in Rotterdam consensus PCOS vs non-PCOS patients undergoing IVF?


Journal

Journal of assisted reproduction and genetics
ISSN: 1573-7330
Titre abrégé: J Assist Reprod Genet
Pays: Netherlands
ID NLM: 9206495

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 16 05 2022
accepted: 17 08 2022
pubmed: 28 8 2022
medline: 28 10 2022
entrez: 27 8 2022
Statut: ppublish

Résumé

To evaluate the oocyte potential to develop to blastocyst in Rotterdam consensus PCOS in women with hyper-responses requiring freeze-all embryos. Retrospective, single-academic center, cohort study of 205 patients who underwent freeze-all antagonist IVF cycles for OHSS risk between 2013 and 2019. Women in the PCOS group (n = 88) were diagnosed per the 2003 Rotterdam criteria. Control patients (n = 122) had no evidence of hyperandrogenism or menstrual disturbance. Data was compared by t-tests, chi-squared tests, or multivariate logistic regression (SPSS). Frozen blastocysts were Gardner's grade BB or better. There was no difference in terms of number of oocytes collected (PCOS vs non-PCOS 27.7 ± 9.4 vs 25.9 ± 8.2, p = 0.157), number of MII (20.7 ± 8.0 vs 19.1 ± 6.6, p = 0.130), number of 2PN fertilized (15.6 ± 7.4 vs 14.4 ± 5.9, p = 0.220), and number of frozen blastocysts (7.8 ± 4.9 vs 7.1 ± 3.8, p = 0.272). In addition, fertilization rates (74 ± 17% vs 75 ± 17%, p = 0.730), blastulation rates per 2PN (51 ± 25% vs 51 ± 25%, p = 0.869), and blastulation rates per mature oocytes (37 ± 18% vs 37 ± 15%, p = 0.984) were all comparable between PCOS and controls, respectively. Moreover, there was no difference when comparing PCOS and controls in pregnancy rates (45/81 vs 77/122, p = 0.28) and clinical pregnancy rates (34/81 vs 54/122, p = 0.75), respectively. Multivariate logistic regression controlling for confounders failed to alter these results. PCOS subjects do not seem to have altered oocyte potential as measured by number of MII oocytes collected, fertilization, and blastulation rates when compared to high-responder controls, with similar magnitude of stimulation.

Identifiants

pubmed: 36029372
doi: 10.1007/s10815-022-02598-7
pii: 10.1007/s10815-022-02598-7
pmc: PMC9596635
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2311-2316

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Fertil Steril. 1995 Sep;64(3):564-7
pubmed: 7641911
Fertil Steril. 1996 Jun;65(6):1190-5
pubmed: 8641496
Gynecol Obstet Fertil. 2003 Apr;31(4):350-4
pubmed: 12821065
Reprod Biomed Online. 2004 Apr;8(4):419-30
pubmed: 15149566
J Gynecol Obstet Biol Reprod (Paris). 2009 Apr;38(2):133-43
pubmed: 19179017
Hum Reprod. 1997 Mar;12(3):474-7
pubmed: 9130743
Fertil Steril. 1997 Dec;68(6):1017-21
pubmed: 9418690
Hum Reprod. 1995 Aug;10(8):2125-35
pubmed: 8567853
Hum Reprod. 2018 Sep 1;33(9):1602-1618
pubmed: 30052961
Clin Endocrinol (Oxf). 2004 Jan;60(1):67-74
pubmed: 14678290
Eur J Obstet Gynecol Reprod Biol. 2021 Apr;259:146-152
pubmed: 33676123
Hum Reprod. 2012 Aug;27 Suppl 1:i2-21
pubmed: 22811312
BMC Med. 2010 Jun 30;8:41
pubmed: 20591140
Hum Reprod Update. 2011 Jan-Feb;17(1):17-33
pubmed: 20639519
J Clin Endocrinol Metab. 2003 Nov;88(11):5456-61
pubmed: 14602789
Hum Reprod. 1990 Oct;5(7):816-8
pubmed: 2266154
Hum Reprod. 1999 Feb;14(2):354-8
pubmed: 10099978
Fertil Steril. 1999 Sep;72(3):401-5
pubmed: 10519607
J Reprod Immunol. 1998 Aug;39(1-2):13-9
pubmed: 9786450
Arch Gynecol Obstet. 2008 Mar;277(3):239-44
pubmed: 17899140
Hum Reprod Update. 2006 Jan-Feb;12(1):13-21
pubmed: 16123051
Endocrine. 2019 Jun;64(3):685-689
pubmed: 30900204
Arch Gynecol Obstet. 2010 Aug;282(2):199-205
pubmed: 20182736

Auteurs

Veronique Bellemare (V)

Fertility Clinic, McGill University Health Center, Montreal, QC, Canada. veronique.bellemare.1@ulaval.ca.

Keren Rotshenker-Olshinka (K)

Fertility Clinic, McGill University Health Center, Montreal, QC, Canada.

Laura Nicholls (L)

Fertility Clinic, McGill University Health Center, Montreal, QC, Canada.

Alyson Digby (A)

Fertility Clinic, McGill University Health Center, Montreal, QC, Canada.

Amrita Pooni (A)

Fertility Clinic, McGill University Health Center, Montreal, QC, Canada.

Einav Kadour-Peero (E)

Fertility Clinic, McGill University Health Center, Montreal, QC, Canada.

Weon-Young Son (WY)

Fertility Clinic, McGill University Health Center, Montreal, QC, Canada.

Michael H Dahan (MH)

Fertility Clinic, McGill University Health Center, Montreal, QC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH